Particle Sciences to Chair Session and Present on its SATx Technology at the 249th ACS National Meeting

Particle Sciences, Inc. (PSI) will be chairing a session at the ACS National Meeting in Denver on 24 March 2015 addressing protein conjugates and presenting on its newly launched decorated nanoparticle biopharmaceutical platform: Surface Arrayed Therapeutics, SATx.

Dr Bob Becker, VP of Biologics Sales and Business Development will discuss SATx in a talk entitled: Nanoparticle Formulations Linking Pharmaceutical Components by Electrostatic and Hydrophobic Binding: A Faster and More Flexible Alternative to ADCs. Dr Becker states: "Nanoparticles with engineered interiors and surfaces can non-covalently "link" large biopharmaceuticals and small molecule pharmaceuticals forming effective targeted delivery vehicles: for instance, a chemotherapeutic combined with a tumour-specific antibody. Like the traditional ADC approach, SATx associates antigen-specific antibodies and small molecules but, in contrast to ADCs, enables a far more tunable drug-to-antibody ratio without problematic conjugation chemistries. SATx will be capable delivering a far broader range of pharmaceuticals than has been possible with typical ADC approaches and promises to be effective even for disease targets with low antigen copy numbers on their surfaces. The elimination of conjugation chemistries should also reduce regulatory burden for targeted drug delivery and, when applied to vaccines, can improve potency and safety."

In addition, Dr Robert W. Lee, VP Pharmaceutical Development Services, will be chairing a session on "Protein Conjugates: From Basic Principles to Clinically Active Drug". According to Dr Lee, "SATx leverages PSI’s core strengths in surface chemistry and particle fabrication. We are very excited to add this technology to our solution set for our Biopharmaceutical clients."